Brief Reports
Copyright ©The Author(s) 2004.
World J Gastroenterol. Jul 1, 2004; 10(13): 1961-1963
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1961
Table 1 Primers designed for detection of CYP2C19*2
GenotypeSequences
Wild-typeForward5’-AATTACAACCAGAGAGCTTGGC-3’
Reverse5’-GTAATTTGTTATGGGTTCCC-3’
MutantForward5’-AATTACAACCAGAGAGCTTGGC-3’
Reverse5’-GTAATTTGTTATGGGTTCCT-3’
Table 2 Primers designed for detection of CYP2C19*3
GenotypeSequences
Wild-typeForward5’-TATTATTATCTGTTAACTAATATGA-3’
Reverse5’-AACTTGGCCTTACCTGGATC-3’
MutantForward5’-TATTATTATCTGTTAACTAATATGA-3’
Reverse5’-AACTTGGCCTTACCTGGATT-3’
Table 3 Frequencies of EMs and PMs in different cancer groups and control group
GroupTotalEMs (*1/*1, *1/*2 , *1/*3)
PMs (*2/*2,*2/*3)
casesCases%Cases%
Esophagus cancer1358965.94634.1
Stomach cancer14810168.24731.8
Lung cancer21213965.67334.4
Bladder cancer11210795.554.5
Control37232086.05214.0